

Todd E Defor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415555/publications.pdf>

Version: 2024-02-01

40
papers

5,014
citations

623188

14
h-index

433756

31
g-index

40
all docs

40
docs citations

40
times ranked

5517
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057.	0.6	1,574
2	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070.	0.6	926
3	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , 2007, 110, 3064-3070.	0.6	489
4	Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 387-394.	2.0	367
5	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	0.6	357
6	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	0.6	333
7	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	0.6	307
8	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
9	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980.	2.5	164
10	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 483-494.	2.0	74
11	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436.	2.5	39
12	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
13	Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460.	2.0	27
14	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 866-872.	2.0	19
15	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	2.3	18
16	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <i>Blood Advances</i> , 2021, 5, 1352-1359.	2.5	14
17	Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System. <i>Blood</i> , 2012, 120, 2011-2011.	0.6	14
18	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. <i>Modern Pathology</i> , 2019, 32, 560-567.	2.9	10

#	ARTICLE	IF	CITATIONS
19	An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 81-88.	2.0	9
20	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
21	Association of Iron Overload with Survival and Complications in Allogeneic Hematopoietic Cell Transplant Recipients: Prospective Cohort Study Using R2-MRI Measured Liver Iron Content. <i>Blood</i> , 2012, 120, 1961-1961.	0.6	8
22	Infusion reactions in natural killer cell immunotherapy: a retrospective review. <i>Cytotherapy</i> , 2021, 23, 627-634.	0.3	7
23	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 667.e1-667.e5.	0.6	6
24	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 225-225.	0.6	6
25	Pulmonary Risk Factors in Allogeneic Transplantation for Hurler Syndrome.. <i>Blood</i> , 2004, 104, 2154-2154.	0.6	3
26	New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. <i>Blood</i> , 2007, 110, 41-41.	0.6	3
27	Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	3
28	High cutaneous amphiregulin expression predicts fatal acute <sc>graft-versus-host</sc> disease. <i>Journal of Cutaneous Pathology</i> , 2022, , .	0.7	2
29	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 2317-2324.	2.5	1
30	Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy: A Modern, Single-Institution Experience. <i>Blood</i> , 2010, 116, 3543-3543.	0.6	1
31	SEMIPARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Statistica Sinica</i> , 2019, 29, 1489-1509.	0.2	1
32	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , .	2.5	1
33	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. <i>Blood</i> , 2004, 104, 1817-1817.	0.6	0
34	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. <i>Blood</i> , 2004, 104, 2148-2148.	0.6	0
35	Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.. <i>Blood</i> , 2005, 106, 842-842.	0.6	0
36	Incidence and Outcomes of Immune Thrombocytopenia (ITP) Following Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1316-1316.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Impact of Graft Source on Immune Recovery: Comparisons Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. Blood, 2010, 116, 3731-3731.	0.6	0
38	Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. Blood, 2010, 116, 3531-3531.	0.6	0
39	Intermittent Zoledronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2012, 120, 1965-1965.	0.6	0
40	Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , .	1.3	0